STAT News: A month in, TrumpRx falls short of president’s grand promises

“For several patients in our community, TrumpRx prices are the same or even higher than what they currently pay with insurance,” Merith Basey, executive director of Patients For Affordable Drugs, said in a statement to STAT. “While continued efforts to lower prescription drug prices are encouraged, this program’s design does not address the root cause of high drug costs in the U.S.: the monopolistic pricing strategies of the pharmaceutical industry that prioritize profits over patients.”